Skip to main content

Systemic Inflammatory Response Syndrome

0
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Baxter International
3 programs
Peripheral Intravenous AnalysisN/A
continuous venovenous hemodialysisN/A
septeXN/A
Vantive
VantiveIL - Deerfield
2 programs
continuous venovenous hemodialysisN/A
septeXN/A
Baxter
BaxterCosta Rica - Cartago
2 programs
continuous venovenous hemodialysisN/A1 trial
septeXN/A1 trial
Active Trials
NCT00875888Terminated80Est. Jun 2009
NCT01579396Withdrawn0Est. Dec 2013
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Goal-directed Therapeutic ProtocolN/A1 trial
Active Trials
NCT01293500Terminated230Est. Nov 2014
InflaRx
InflaRxJENA, Germany
1 program
IFX-1PHASE_21 trial
Active Trials
NCT02866825Completed116Est. Jan 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InflaRxIFX-1
BaxtersepteX
Human BioSciencesGoal-directed Therapeutic Protocol
Baxtercontinuous venovenous hemodialysis

Clinical Trials (4)

Total enrollment: 426 patients across 4 trials

NCT02866825InflaRxIFX-1

Studying Complement Inhibition in Complex Cardiac Surgery

Start: May 2016Est. completion: Jan 2017116 patients
Phase 2Completed
NCT01579396BaxtersepteX

High Cut Off Dialysis in Systemic Inflammatory Response Syndrome Patients After Cardiac Surgery

Start: Apr 2012Est. completion: Dec 20130
N/AWithdrawn
NCT01293500Human BioSciencesGoal-directed Therapeutic Protocol

Goal-directed Resuscitative Interventions During Pediatric Inter-facility Transport (The GRIPIT Trial)

Start: Oct 2010Est. completion: Nov 2014230 patients
N/ATerminated
NCT00875888Baxtercontinuous venovenous hemodialysis

High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock

Start: Feb 2004Est. completion: Jun 200980 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Systemic Inflammatory Response Syndrome | Pipeline & Competitive Landscape | Formulate